Literature DB >> 10768951

Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis.

D A Schaefer1, B A Auerbach-Dixon, M W Riggs.   

Abstract

The coccidian parasite Cryptosporidium parvum causes diarrhea in humans, calves, and other mammals. Neither immunization nor parasite-specific pharmaceuticals that are consistently effective against this organism are available. While polyclonal antibodies against whole C. parvum reduce infection, their efficacy and predictability are suboptimal. We hypothesized that passive immunization against cryptosporidiosis could be improved by using neutralizing monoclonal antibodies (MAbs) targeting functionally defined antigens on the infective stages. We previously reported that the apical complex and surface-exposed zoite antigens CSL, GP25-200, and P23 are critical in the infection process and are therefore rational targets. In the present study, a panel of 126 MAbs generated against affinity-purified CSL, GP25-200, and P23 was characterized to identify the most efficacious neutralizing MAb formulation targeting each antigen. To identify neutralizing MAbs, sporozoite infectivity following exposure to individual MAbs was assessed by enzyme-linked immunosorbent assay. Of 126 MAbs evaluated, 47 had neutralizing activity. These were then evaluated individually in oocyst-challenged neonatal mice, and 14 MAbs having highly significant efficacy were identified for further testing in formulations. Epitope specificity assays were performed to determine if candidate MAbs recognized the same or different epitopes. Formulations of two or three neutralizing MAbs, each recognizing distinct epitopes, were then evaluated. A formulation of MAbs 3E2 (anti-CSL [alphaCSL]), 3H2 (alphaGP25-200), and 1E10 (alphaP23) provided highly significant additive efficacy over that of either individual MAbs or combinations of two MAbs and reduced intestinal infection by 86 to 93%. These findings indicate that polyvalent neutralizing MAb formulations targeting epitopes on defined antigens may provide optimal passive immunization against cryptosporidiosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768951      PMCID: PMC97466          DOI: 10.1128/IAI.68.5.2608-2616.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

Review 1.  Passive antibody therapies: progress and continuing challenges.

Authors:  A Casadevall
Journal:  Clin Immunol       Date:  1999-10       Impact factor: 3.969

2.  Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation.

Authors:  M P Woodward; W W Young; R A Bloodgood
Journal:  J Immunol Methods       Date:  1985-04-08       Impact factor: 2.303

3.  Enteric lesions and diarrhea in gnotobiotic calves monoinfected with Cryptosporidium species.

Authors:  J Heine; J F Pohlenz; H W Moon; G N Woode
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

4.  Distinction of epitopes by monoclonal antibodies.

Authors:  C Stähli; V Miggiano; J Stocker; T Staehelin; P Häring; B Takács
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Neutralization-sensitive epitopes are exposed on the surface of infectious Cryptosporidium parvum sporozoites.

Authors:  M W Riggs; T C McGuire; P H Mason; L E Perryman
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

6.  Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients.

Authors:  J Nord; P Ma; D DiJohn; S Tzipori; C O Tacket
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

7.  Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice.

Authors:  R Fayer; A Guidry; B L Blagburn
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

8.  Antibody-induced ultrastructural changes of malarial sporozoites.

Authors:  A H Cochrane; M Aikawa; M Jeng; R S Nussenzweig
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

9.  Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum.

Authors:  B L Ungar; D J Ward; R Fayer; C A Quinn
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

10.  Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro.

Authors:  D Mazier; S Mellouk; R L Beaudoin; B Texier; P Druilhe; W Hockmeyer; J Trosper; C Paul; Y Charoenvit; J Young
Journal:  Science       Date:  1986-01-10       Impact factor: 47.728

View more
  12 in total

1.  Systemic antibody responses to the immunodominant p23 antigen and p23 polymorphisms in children with cryptosporidiosis in Bangladesh.

Authors:  Anoli J Borad; Geneve M Allison; David Wang; Sabeena Ahmed; Mohammad M Karim; Anne V Kane; Joy Moy; Patricia L Hibberd; Sitara Swarna Rao Ajjampur; Gagandeep Kang; Stephen B Calderwood; Edward T Ryan; Elena Naumova; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Authors:  Deborah A Schaefer; Dana P Betzer; Kylie D Smith; Zachary G Millman; Hannah C Michalski; Sarah E Menchaca; Jennifer A Zambriski; Kayode K Ojo; Matthew A Hulverson; Samuel L M Arnold; Kasey L Rivas; Rama S R Vidadala; Wenlin Huang; Lynn K Barrett; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; Michael W Riggs
Journal:  J Infect Dis       Date:  2016-10-17       Impact factor: 5.226

Review 3.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

Review 4.  Cryptosporidium pathogenicity and virulence.

Authors:  Maha Bouzid; Paul R Hunter; Rachel M Chalmers; Kevin M Tyler
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

5.  Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.

Authors:  Michael W Riggs; Deborah A Schaefer; Sushila J Kapil; Lise Barley-Maloney; Lance E Perryman
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Characterization of an intestinal epithelial cell receptor recognized by the Cryptosporidium parvum sporozoite ligand CSL.

Authors:  R C Langer; D A Schaefer; M W Riggs
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice.

Authors:  Michael Imboden; Michael W Riggs; Deborah A Schaefer; E Jane Homan; Robert D Bremel
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Elongation factor-1α is a novel protein associated with host cell invasion and a potential protective antigen of Cryptosporidium parvum.

Authors:  Makoto Matsubayashi; Isao Teramoto-Kimata; Shigehiko Uni; Hyun S Lillehoj; Haruo Matsuda; Masaru Furuya; Hiroyuki Tani; Kazumi Sasai
Journal:  J Biol Chem       Date:  2013-09-30       Impact factor: 5.157

9.  Biochemical and functional characterization of CpMuc4, a Cryptosporidium surface antigen that binds to host epithelial cells.

Authors:  John Paluszynski; Zachary Monahan; Maura Williams; Olivia Lai; Christopher Morris; Patrick Burns; Roberta O'Connor
Journal:  Mol Biochem Parasitol       Date:  2014-03-29       Impact factor: 1.759

10.  Antibody fusions reduce onset of experimental Cryptosporidium parvum infection in calves.

Authors:  Michael Imboden; Deborah A Schaefer; Robert D Bremel; E Jane Homan; Michael W Riggs
Journal:  Vet Parasitol       Date:  2012-03-06       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.